Short Interest in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Declines By 30.9%

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 269,500 shares, a decline of 30.9% from the February 28th total of 389,900 shares. Currently, 1.6% of the company’s stock are sold short. Based on an average trading volume of 333,500 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Trading of Chemomab Therapeutics

Large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in shares of Chemomab Therapeutics during the fourth quarter worth approximately $26,000. XTX Topco Ltd grew its holdings in Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after acquiring an additional 9,706 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in shares of Chemomab Therapeutics in the 3rd quarter worth about $1,907,000. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Chemomab Therapeutics Price Performance

NASDAQ CMMB traded up $0.03 on Friday, reaching $1.13. The company had a trading volume of 98,410 shares, compared to its average volume of 207,791. Chemomab Therapeutics has a 1 year low of $0.58 and a 1 year high of $2.55. The firm has a 50-day moving average of $1.70 and a 200-day moving average of $1.68. The firm has a market capitalization of $16.23 million, a PE ratio of -1.13 and a beta of 0.54.

Wall Street Analyst Weigh In

Separately, Maxim Group raised their price objective on Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, February 20th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).